Page last updated: 2024-12-06

6-nitrochrysene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-nitrochrysene: RN given refers to cpd with locant for nitro group in position 6 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24121
CHEMBL ID82858
CHEBI ID82351
SCHEMBL ID710252
MeSH IDM0109904

Synonyms (30)

Synonym
chebi:82351 ,
6-nitro-chrysene
CHEMBL82858 ,
6-nitrochrysene [nitroarenes]
nsc 407609
chrysene, 6-nitro-
6-nitrochrysene
brn 2134652
ccris 2975
nsc407609
7496-02-8
nsc-407609
bdbm50128865
C19271
unii-82zk83o33y
82zk83o33y ,
hsdb 7770
3-05-00-02383 (beilstein handbook reference)
6-nitrochrysene [hsdb]
nitrochrysene, 6-
6-nitrochrysene [iarc]
SCHEMBL710252
AKOS024386611
4-nitrochrysene #
UAWLTQJFZUYROA-UHFFFAOYSA-N
DTXSID9075454
6-nitrochrysene, bcr(r) certified reference material
Q27155892
FT-0778180
6-nitrochrysene (purity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 6-Nitrochrysene, a known direct-acting mutagen in bacteria, was highly toxic to the rat but not to the human cells."( Cytotoxicity and keratinocyte microsome-mediated mutagenic activation of carcinogens in cultured epidermal cells.
Chun, HS; Kado, NY; Kuzmicky, PA; Rice, RH; Rucoba, L, 2000
)
1.22

Dosage Studied

ExcerptRelevanceReference
"55 mumol) with the dose-response relationship indicating a saturation of tumor multiplicity at approximately 7 tumors/animal."( Dose-response relationships of the tumorigenicity of cyclopenta[cd]pyrene, benzo[a]pyrene and 6-nitrochrysene in a newborn mouse lung adenoma bioassay.
Busby, WF; Cornelisse, J; Kellenbach, ER; Lugtenburg, J; Stevens, EK, 1988
)
0.49
" Depending on the tissue and the dosing schedule, the total level of DNA modification in animals dosed with [3H]NC was 2- to 9-fold higher than in animals dosed with [3H]AC."( Carcinogen-DNA adduct formation in the lungs and livers of preweanling CD-1 male mice following administration of [3H]-6-nitrochrysene, [3H]-6-aminochrysene, and [3H]-1,6-dinitropyrene.
Delclos, KB; Dooley, KL; Fu, PP; Kadlubar, FF; Walker, RP, 1987
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbopolycyclic compoundA polyclic compound in which all of the ring members are carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Ki6.70000.60005.54678.9800AID93178
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID93178Kinetic inhibition constant of compound with Trypanosoma cruzi Hypoxanthine Phosphoribosyltransferase (HPRT)2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Analysis of 6-(2,2-Dichloroacetamido)chrysene interaction with the hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (26.47)18.7374
1990's24 (35.29)18.2507
2000's14 (20.59)29.6817
2010's9 (13.24)24.3611
2020's3 (4.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.92 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (97.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]